Teva Pharmaceutical Industries Ltd. (TEVA)

24.22
NYSE : Health Technology
Prev Close 24.11
Day Low/High 23.45 / 24.37
52 Wk Low/High 10.85 / 25.14
Avg Volume 10.12M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 23.38B
EPS -16.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Buffett Ups Stake in Teva

Buffett Ups Stake in Teva

Warren Buffett's Berkshire Hathaway increases its stake in the drugmaker to 43.2 million shares from 40.5 million shares at the end of March.

Teva Announces Updated Indication And Vial Presentation For GRANIX® (tbo-filgrastim) Injection In United States

Teva Announces Updated Indication And Vial Presentation For GRANIX® (tbo-filgrastim) Injection In United States

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.

3 Great Stocks to Buy If You Love Your Pet

3 Great Stocks to Buy If You Love Your Pet

The animal health market continues to be strong, and so is the outlook. Here are several plays on the space and why you should make them.

Teva Reports Second Quarter 2018 Financial Results

Teva Reports Second Quarter 2018 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended June 30, 2018.

Tesla Earnings, Trade Tariffs, Starbucks and Sonos - 5 Things You Must Know

Tesla Earnings, Trade Tariffs, Starbucks and Sonos - 5 Things You Must Know

U.S. stock futures trade lower on Thursday,, sparked by a tougher stance on China tariffs from the White House; Tesla jumps as revenue tops forecasts; Starbucks partners with Alibaba for a delivery business in China.

Teva Highlights Key Milestones Achieved In The 2017 Social Impact Report

Teva Highlights Key Milestones Achieved In The 2017 Social Impact Report

Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its annual social impact report, highlighting achievements related to the two pillars that drive the Company's initiatives: building healthy communities and leading a responsible...

Teva To Report Second Quarter 2018 Financial Results On August 2, 2018

Teva To Report Second Quarter 2018 Financial Results On August 2, 2018

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it will release its second quarter 2018 financial results on Thursday, August 2, 2018 at 7:00 a.

Teva Announces Launch Of A Generic Version Of Uceris® In The United States

Teva Announces Launch Of A Generic Version Of Uceris® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Uceris ®1 (budesonide) extended-release tablets, 9 mg, in the U.

Teva To Present New Fremanezumab Data, Including Long-Term Data, At The American Headache Society's 60th Annual Scientific Meeting

Teva To Present New Fremanezumab Data, Including Long-Term Data, At The American Headache Society's 60th Annual Scientific Meeting

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced 23 abstracts, one late-breaking poster and three oral presentations of fremanezumab for the preventive treatment of migraine which will be presented at the American Headache...

China Pledges Help With Fentanyl Imports; Says U.S. Must Curb Opioid Demand

China Pledges Help With Fentanyl Imports; Says U.S. Must Curb Opioid Demand

Despite a growing trade war between the U.S, and China, drug officials in that country have pledged to try to stop the flow of fentanyl into the U.S.

Teva Provides Update On Clinical Trial Of Fremanezumab For Use In Chronic Cluster Headache

Teva Provides Update On Clinical Trial Of Fremanezumab For Use In Chronic Cluster Headache

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced a change in the clinical development program of fremanezumab in chronic cluster headache.

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

Sirius XM Radio, Teva Pharmaceuticals: 'Mad Money' Lightning Round

Sirius XM Radio, Teva Pharmaceuticals: 'Mad Money' Lightning Round

Jim Cramer weighs in on Sirius XM Radio, Teva Pharmaceuticals, iQIYI, Blue Apron, Shopify, Incyte, E*Trade Financial and more.

Big Turnaround Stories: Cramer's 'Mad Money' Recap (Wednesday 5/23/18)

Big Turnaround Stories: Cramer's 'Mad Money' Recap (Wednesday 5/23/18)

Jim Cramer tells investors to keep their eyes open for companies making changes -- that's what's being rewarded.

Teva Confirms September PDUFA Date For Fremanezumab

Teva Confirms September PDUFA Date For Fremanezumab

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed that the U.

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Here's what you need to know now for Friday, May 18.

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.

Dow Closes Higher as Wall Street Weighs Rising Rates

Dow Closes Higher as Wall Street Weighs Rising Rates

The Dow, S&P 500 and Nasdaq all rose on Wednesday.

Teva Shares Jump After Warren Buffett Doubles Stake in Drugmaker

Teva Shares Jump After Warren Buffett Doubles Stake in Drugmaker

Berkshire Hathaway hiked its stake in the drugmaker, which is undergoing a restructuring, to 40.5 million shares as of the end of March.

CORRECTING And REPLACING Teva Announces Publication Of Phase III Trial Data Of Fremanezumab For The Preventive Treatment Of Episodic Migraine In The Journal Of The American Medical Association

CORRECTING And REPLACING Teva Announces Publication Of Phase III Trial Data Of Fremanezumab For The Preventive Treatment Of Episodic Migraine In The Journal Of The American Medical Association

First bulleted paragraph, second sentence of release dated May 15, 2018 should contain the numbers 4.

Teva Shows Progress on Restructuring But Investors Want More

Teva Shows Progress on Restructuring But Investors Want More

The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.

Dow Rises Slightly but S&P 500 and Nasdaq Finish Lower After Volatile Session

Dow Rises Slightly but S&P 500 and Nasdaq Finish Lower After Volatile Session

Shares of Tesla Inc., which reported earnings on Wednesday, fell by 5.5%

Teva Shares Spike After Q1 Earnings Beat, Full Year Forecast Boost

Teva Shares Spike After Q1 Earnings Beat, Full Year Forecast Boost

Teva shares edged into positive territory for the year Thursday after a stronger-than-expected start to the year allowed CEO Kåre Schultz to boost the generic drugmaker's 2018 earnings forecast.

Teva Reports First Quarter 2018 Financial Results

Teva Reports First Quarter 2018 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2018.

Teva To Present AUSTEDO® (deutetrabenazine) Tablets Data At The American Psychiatric Association 2018 Annual Meeting

Teva To Present AUSTEDO® (deutetrabenazine) Tablets Data At The American Psychiatric Association 2018 Annual Meeting

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced new scientific abstracts for AUSTEDO ® (deutetrabenazine) tablets will be presented at the American Psychiatric Association (APA) 2018 Annual Meeting in New York from May 5-9.

Teva Presents New Long-Term Data Demonstrating Efficacy And Safety Of COPAXONE® (glatiramer Acetate Injection) 40 Mg/mL

Teva Presents New Long-Term Data Demonstrating Efficacy And Safety Of COPAXONE® (glatiramer Acetate Injection) 40 Mg/mL

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE ® (glatiramer...

TheStreet Quant Rating: D+ (Sell)